What Is Nerolidol? A Terpene, Read Closely

Nerolidol in ten points

1. Two facts about this molecule sit oddly together. In Europe it reaches people constantly, smelled and tasted in ordinary products, while the name on the ingredient list goes unread [1]. Familiar in the nose, anonymous on paper. Almost nobody looks it up, and almost everybody has met it.
2. It is a terpene. That family runs to more than 40,000 compounds described in nature, which makes it one of the broadest groups in plant chemistry. Nerolidol occurs in species with a floral odour, and a fair number of those species are herbs with a long history in folk medicine.
3. The industrial figure is public and unglamorous: between 10 and 100 metric tonnes used per year, mainly in cosmetics and in cleaning products [1]. The stated purpose is scent. Not preservation, not texture, not function. Scent.
4. Stability is the commercial driver behind that demand [1]. A fragrance ingredient that keeps its character inside a finished formula is worth specifying, because the tenth production run has to smell like the first.
5. Food is a separate file. In the United States the FDA classes nerolidol as a safe flavouring, and manufacturers apply it in the role of flavour enhancer [1]. Same molecule, different paperwork, different regulator.
6. Chemically it is a sesquiterpene alcohol, and it also travels under a systematic name, 3-hydroxy-3,7,11-trimethyl-1,6,10-dodecatriene, which is how you will find it in older chemistry indexes.
7. Hemp readers usually meet the word through Russo 2011 [2], which named nerolidol among the candidate terpenes for interaction with certain cannabinoids. A proposal set out in a review, and nothing wider than that.
8. Everything measured so far is preclinical. The papers cited here ran in animal models: Wattenberg 1991 [4], Klopell 2007 [7], Nogueira Neto 2013 [6], Costa 2015 [5] and Fonsêca 2016 [3].
9. Two plant names carry much of that work. Klopell 2007 isolated nerolidol from the essential oil of Baccharis dracunculifolia [7], and Costa 2015 worked with the leaf essential oil of Zornia brasiliensis, which was high in nerolidol [5].
10. Human testing is absent from those animal studies [5]. That single line sets the reading mode for the rest of this page: literal. Several findings below rest on one study each, and a number from an animal model stays a number from that model.

Seven entries, one table

Scent first, everything else later

Most of what is known about nerolidol with real certainty has nothing to do with pharmacology. It has to do with factories. The reported industrial figure sits between 10 and 100 metric tonnes a year, and the sectors are cosmetics and cleaning products [1]. The listed purpose is scent, and only scent.

Stability explains the demand [1]. A fragrance ingredient that holds its character inside a finished formula is worth specifying, because whoever signs off a production batch needs consistency more than novelty. Nerolidol holds up. It is a dull virtue. It is also the whole reason the tonnage exists.

Food sits in its own file. In the United States, the FDA classes nerolidol as a safe flavouring, and manufacturers use it in the role of flavour enhancer [1]. In Europe the situation is more ordinary still: people smell it and taste it in things they buy, while the name itself stays unread on the label [1].

The botany is wide. Terpenes as a family run past 40,000 described compounds, and nerolidol turns up in plant species with a floral odour, a number of them herbs with a long folk-medicine record. Broad occurrence, a pleasant odour and stability in a formula. That combination is what puts a molecule on a perfumer's shelf and keeps it there.

• Volume in industry: roughly 10 to 100 metric tonnes per year [1].
• Sectors: cosmetics and cleaning products, for scent [1].
• Status in US food: FDA safe flavouring, applied by manufacturers as a flavour enhancer [1].
• European consumer contact: smelled and tasted, name unread on the label [1].
• Why formulators keep specifying it: stability inside the finished product [1].
• Botanical spread: plant species with a floral odour, folk-medicine herbs among them.
• Family size: more than 40,000 terpenes described in nature.

Next to the cannabinoids

Anyone reading about hemp meets this molecule through one paper. Russo 2011 [2] set out the proposal usually called the entourage effect: the idea, at review level, that cannabinoids and the aromatic terpenes alongside them may interact rather than act separately. Nerolidol appears there as a candidate terpene for interaction with certain cannabinoids [2]. Candidate is the working word. A review can propose a mechanism. It does not measure one, and no human data is attached to that proposal.

Full-spectrum, while we are on the vocabulary, simply means an extract that keeps a broader set of hemp compounds instead of isolated CBD. It is a description of what stayed in the bottle, not a promise about anything.

So what can actually be checked? The contents of that bottle. Since 2014 we have published independent analyses across the CBD oil range, and the reasoning has not shifted since the first one: claims are easy, results are checkable. If a label states a number, the report should state the same number, and you should be able to read both before the product becomes part of your routine.

That habit came before the current market did. Cibdol is one of the first CBD brands in the world, Swiss from day one, formulating and testing while much of the category was still busy asserting. Basel discipline, applied to a plant extract. Nothing more mysterious than that.

A batch report also has limits, and they matter on a page like this one. It describes the material in front of you: what was measured, how much of it was there, and who did the measuring. It says nothing about what a compound does inside a person, because it was never built to. The animal studies cited here describe mouse models [3][4][6][7]. A certificate describes a batch. Two documents, two questions, and the honest approach is to keep them apart rather than let one borrow credibility from the other.

Where the record stops

Several of the findings above rest on a single study each. That is not a footnote, it is the state of the file. One paper is a starting point for further work rather than a conclusion, and in preclinical research the second attempt at the same experiment is where the arguments get interesting.

Nogueira Neto 2013 [6] is a clean example. The authors describe their antioxidant readings as neuroprotective in that model. One preclinical mouse study, one brain region. Accurate at that scale, silent about everything beyond it.

Klopell 2007 [7] carries more detail, and the detail cuts in both directions. In the ethanol-induced ulcer model of that study, inhibition came in at 52.63% at 250 mg/kg and 87.63% at 500 mg/kg, while indomethacin-induced ulcers were also inhibited and restraint-stress ulcer formation was lower than in the control group. Two doses, two numbers, one direction. Those milligram-per-kilogram amounts belong to the animal model and convert into nothing on a human scale.

Wattenberg 1991 [4] reads the same way: 33% tumour incidence in the nerolidol group against 82% in the control group of that mouse model, one experiment, no follow-up cited here. Costa 2015 [5] reports a wide band, 1.68% to 38.61% tumour growth reduction in an animal model, and the material tested was a whole leaf essential oil rather than the isolated compound.

Fonsêca 2016 [3] adds a proposed mechanism, the GABAergic system, meaning the network built around the signalling molecule gamma-aminobutyric acid, alongside lower interleukin production in that study, interleukins being the immune-cell signalling molecules involved in inflammation. Proposed. Not settled.

What would move any of this forward is thorough clinical trials, with participants, controls and published results. Until they exist, the absence of human testing in the cited animal studies [5] is a fact about the evidence rather than a space to fill with confident wording. We do not know yet, and saying so costs nothing.

One note for anyone checking sources. Fonsêca 2016 [3] is indexed with a February 2016 date while some reference lists give 2015, which points to online-first publication ahead of print.